Association between in-line filtration and Type I hypersensitivity reactions in pediatric oncology patients receiving intravenous etoposide

• Published in: Pediatric hematology and oncology 2021-04, Vol.38 (3), p.208-215
• Main Authors: Ronsley, Rebecca, Jacques, Lisa, Potts, James E., Clement, Kerri, Dix, David B., Mahon, Paula
• Format: Article
• Language: English
• Subjects: Anaphylaxis; etoposide; hypersensitivity; pediatric
• ISSN: 0888-0018; 1521-0669
• DOI: 10.1080/08880018.2020.1838011

The objective of this study was to describe hypersensitivity reactions with and without the use of in-line filters during intravenous etoposide therapy in pediatric oncology patients. This was a retrospective review of all patients treated in the Division of Oncology/Hematology/Bone Marrow Transplant at British Columbia Children's Hospital with intravenous etoposide between December 1, 2013 and February 1, 2018. Hypersensitivity reactions and anaphylaxis associated with etoposide infusions were compared over time, including 12 months prior to, 27 months during the use of, and for 12 months after the discontinuation of in-line filtration. There were 192 patients (median age 6.0 (IQR 2.8-13.0) years treated with etoposide and 486 etoposide infusions including 137 (28%) before, 261 (54%) during and 88 (18%) after use of in-line filters at our center. Twenty-six of 486 (5%) and 13/486 (3%) of infusions resulted in a type I hypersensitivity reaction and anaphylaxis, respectively. There were 2/137 (1%), 36/261 (14%) and 1/88 (1%) infusion reactions prior to, during and after in-line filter use, respectively. Infusion reactions during the in-line filter period were higher than during the pre-filter (Z = 3.978; p